Device/Diagnostics Quarterly Deal-Making Statistics, Q1 2017
A look at financing, M&A and alliance activity January–March 2017
Medtech companies brought in $2.3 billion in financing in Q1 2017, a slight decrease from Q4 2016; device M&A deals totaled $5.8 billion, a sharp decline from the prior quarter, but there were some billion-dollar deals. Q1 diagnostics financings – totaling $1.2 billion (thanks to a $900 million Series B round by cancer diagnostics company Grail) – showed a significant increase over the preceding quarter, as did the Q1 M&As at $700 million versus the previous $87 million.
You may also be interested in...
M&A Deals Analysis: February Sees Billion-Dollar Buys Bite
Despite being a slow month, megadeals abounded in February, as the medtech M&A market saw a hat-trick of billion-dollar deals. Medtech Insight recorded 12 deals for the month, on par with January's volume but down from 16 in February 2016.
Big Pharma Helps Pour $900m Into Grail
The biggest venture funding round in history, pan-cancer screening test developer Grail has reeled in $900m in the first close of what it hopes will be a $1bn Series B round.
Integra Aims To Bolster Neurology Portfolio With J&J Codman Buy
Only a month after buying the tissue regeneration company Derma Sciences, Integra has announced a much larger acquisition for Codman Neurosurgery. The company says the buy would complement its current neurosurgery portfolio and boost its global reach.